Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
65
Not yet recruiting, industry sponsors, Cardiovascular and metabolic, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting167
- Completed1,732
65 trials
Showing 1 to 25, recently updated first.
- Safty and Efficacy of KH658 in Subjects With Diabetic RetinopathyNot yet recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT07951606 · 48 participants (planned) · Start Feb 2027 · Primary completion Jun 2028
Drug: Ranibizumab · For: Diabetic Retinopathy
Sites: Beijing, China; Chengdu, China
- A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 DiabetesPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07940803 · 300 participants (planned) · Start Nov 13, 2026 · Primary completion Mar 25, 2028
Drug: NNC0662-3168 (Test product-A); Placebo matched to NNC0662-3168 (Test product-A) and 1 more · For: Overweight; Obesity; Type 2 Diabetes Mellitus
Sites: Tempe, Arizona; Lincoln, Nebraska
- Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke PatientsNot yet recruiting
Sinfatin S.LIndustry
NCT07941479 · 80 participants (planned) · Start Nov 30, 2026 · Primary completion Jan 31, 2028
Drug: Rimonabant; Placebo · For: Subacute Stroke
Sites: Albacete, Spain; Badalona, Spain; Córdoba, Spain · 6 sites in all
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Pivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07933328 · 120 participants (planned) · Start Dec 9, 2026 · Primary completion May 7, 2029
Drug: ALN-CIDEB; Placebo · For: Alcohol-Associated Liver Disease; ALD
- HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryNot yet recruiting
HELP Therapeutics, Inc.Industry
NCT07646210 · 12 participants (planned) · Start Feb 2027 · Primary completion Feb 2028
Drug: HiCM-188 Cells · For: Advanced Heart Failure; Ischemic Heart Failure
Sites: Houston, Texas
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients With Uncontrolled Hypertension Who Are Receiving One or More Background Drug TreatmentsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07927556 · 260 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: Dose 1 of QLS1410; Dose 2 of QLS1410 and 2 more · For: Uncontrolled Hypertension
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin TherapyPivotal-lookingNot yet recruiting
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
NCT07929350 · 150 participants (planned) · Start Nov 20, 2026 · Primary completion Jan 15, 2028
Drug: Fuling Yunhua Granules; Dihuang Baoyuan Granules and 4 more · For: Diabetes Mellitus, Type 2
Sites: Beijing, China
- A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityPivotal-lookingNot yet recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07929298 · 180 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 3, 2027
Drug: ecnoglutide tablet; placebo with matching dosage · For: Overweight , Obesity; Weight Management
Sites: Luoyang, China
- A Study of Bimagrumab in Participants With HFpEFPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07920887 · 540 participants (planned) · Start Nov 2026 · Primary completion Jul 2029
Drug: Bimagrumab; Placebo · For: Heart Failure, Diastolic; Diastolic Heart Failure; Heart Failure, Normal Ejection Fraction and 1 more
Sites: Van Nuys, California; North Miami Beach, Florida; Dallas, Texas · 9 sites in all
- A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusPivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07923357 · 364 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 30, 2027
Drug: SAL0150 dose 1; SAL0150 dose 2 and 5 more · For: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM
Sites: Beijing, China
- A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic StrokePivotal-lookingNot yet recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07903701 · 1,092 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 30, 2029
Drug: SIM0811 Dose Level A (Phase II); SIM0811 Dose Level B (Phase II) and 4 more · For: Acute Ischemic Stroke AIS
- A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without DiabetesPivotal-lookingNot yet recruiting
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT07918625 · 160 participants (planned) · Start Nov 30, 2026 · Primary completion Aug 1, 2027
Drug: BGM1812 injection / plcaebo; BGM1812 injection / plcaebo and 2 more · For: Overweight or Obese Participants Without Diabetes
Sites: Changsha, China
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle InterventionPivotal-lookingNot yet recruiting
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
NCT07920640 · 150 participants (planned) · Start Nov 20, 2026 · Primary completion Jan 15, 2028
Drug: Fuling Yunhua Granules; Dihuang Baoyuan Granules and 2 more · For: Diabetes Mellitus, Type 2
Sites: Beijing, China
- A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive PatientsPivotal-lookingNot yet recruiting
InnovStone Therapeutics LimitedIndustry
NCT07911735 · 264 participants (planned) · Start Dec 13, 2026 · Primary completion Jul 22, 2027
Drug: SYH2072 Tablets; SYH2072 Tablets and 2 more · For: Uncontrolled Hypertension; Resistant Hypertension
- Rimonabant for Improving Walking Ability in Patients With Chronic StrokeNot yet recruiting
Sinfatin S.LIndustry
NCT07913763 · 80 participants (planned) · Start Nov 30, 2026 · Primary completion Jan 31, 2028
Drug: Rimonabant; Placebo · For: Chronic Stroke
Sites: Albacete, Spain; Badalona, Spain; Córdoba, Spain · 6 sites in all
- A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 DiabetesPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07890376 · 460 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: LY4086940; Placebo · For: Obesity; Overweight
Sites: Chandler, Arizona; Scottsdale, Arizona; Tucson, Arizona · 46 sites in all
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 DiabetesPivotal-lookingNot yet recruiting
Paulex Bio Inc.Industry
NCT07901595 · 147 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 1, 2027
Drug: PAL-119; Placebo · For: Healthy Volunteers and Diabetes Participants
- EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Not yet recruiting
Editas Medicine, Inc.Industry
NCT07894887 · 56 participants (planned) · Start Nov 2026 · Primary completion Jun 2029
Drug: Drug: EDIT-401 · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Charlestown, Australia; Perth, Australia
- A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy SituationsPivotal-lookingNot yet recruiting
Cilcare SASIndustry
NCT07472907 · 135 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: CIL001 (Paliroden); Placebo · For: Cochlear Synaptopathy
- A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 DiabetesNot yet recruiting
Pharmasaga Co. Ltd.Industry
NCT07889505 · 36 participants (planned) · Start Nov 21, 2026 · Primary completion Aug 15, 2028
Drug: PS1; Placebo · For: Type 1 Diabetes Mellitus
IRulya Therapeutics Inc.Industry
NCT07886554 · 60 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Placebo; LAM-001 and 1 more · For: Sarcoidosis Associated Pulmonary Hypertension
Sites: Philadelphia, Pennsylvania
- A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.Not yet recruiting
EktaHIndustry
NCT07882654 · 31 participants (planned) · Start Oct 20, 2026 · Primary completion Feb 5, 2027
Drug: Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120 · For: Obesity / Overweight; Obesity (BMI Equal to or >30)
Sites: Tunis, Tunisia
- A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic StrokePivotal-lookingNot yet recruiting
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT07754825 · 300 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: LT3001 Drug:high dose; LT3001 Drug: low dose and 1 more · For: Acute Ischemic Stroke
Sites: Beijing, China
- Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 DiabetesNot yet recruiting
SeraxisIndustry
NCT07581197 · 9 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Allogeneic pancreatic endocrine cell clusters · For: Diabete Mellitus; Diabete Type 1
- A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose ControlPivotal-lookingNot yet recruiting
Vincentage Pharma Co., LtdIndustry
NCT07872436 · 120 participants (planned) · Start Nov 1, 2026 · Primary completion Jul 1, 2027
Drug: VCT220 tablets; Placebo · For: Type 2 Diabetes Mellitus (DM)
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.